Published in J Pharmacokinet Pharmacodyn on June 13, 2008
IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Res (2009) 1.60
The zinc-dependent protease activity of the botulinum neurotoxins. Toxins (Basel) (2010) 0.84
Adult neuron addition to the zebra finch song motor pathway correlates with the rate and extent of recovery from botox-induced paralysis of the vocal muscles. J Neurosci (2011) 0.82
Temporal characteristics of botulinum neurotoxin therapy. Expert Rev Neurother (2010) 0.80
Proconvulsant actions of intrahippocampal botulinum neurotoxin B in the rat. Neuroscience (2013) 0.79
Kinetic and reaction pathway analysis in the application of botulinum toxin a for wound healing. J Toxicol (2011) 0.77
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Neurotoxins affecting neuroexocytosis. Physiol Rev (2000) 5.42
SV2 is the protein receptor for botulinum neurotoxin A. Science (2006) 4.51
Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol (2004) 3.69
Next generation simulation tools: the Systems Biology Workbench and BioSPICE integration. OMICS (2003) 3.38
Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol (2003) 2.19
Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon (2001) 2.05
The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett (2006) 2.04
Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther (1980) 1.79
The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol (2004) 1.73
Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin. J Protein Chem (1997) 1.55
Kinetic analysis of end plate currents altered by atropine and scopolamine. Mol Pharmacol (1978) 1.45
An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther (2006) 1.22
Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci (2003) 1.21
Botulinum toxin: mechanisms of action. Eur Neurol (2005) 1.16
Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA (2006) 1.14
Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord (2004) 1.10
Entering neurons: botulinum toxins and synaptic vesicle recycling. EMBO Rep (2006) 1.05
An outbreak of botulism in Thailand: clinical manifestations and management of severe respiratory failure. Clin Infect Dis (2006) 1.03
Botulinum neurotoxin A changes conformation upon binding to ganglioside GT1b. Biochemistry (2004) 1.02
Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon (2002) 1.00
Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience (2006) 0.95
Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain. J Neurosci Res (1996) 0.93
Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J Pharmacol Exp Ther (2001) 0.92
Botulinum toxin: a successful therapeutic protein. Curr Med Chem (2004) 0.90
Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. Toxicon (1995) 0.90
Studies on the binding of botulinum toxin type A to the rat phrenic nerve-hemidiaphragm preparation. Neuropharmacology (1974) 0.88
Role of uptake in gamma-aminobutyric acid (GABA)-mediated responses in guinea pig hippocampal neurons. Cell Mol Neurobiol (1985) 0.85
An outbreak of serious illness and death among injecting drug users in England during 2000. J Med Microbiol (2002) 0.84
Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis. Toxicon (2001) 0.83
Localization of sites for 125I-labelled botulinum neurotoxin at murine neuromuscular junction and its binding to rat brain synaptosomes. Toxicon (1982) 0.79
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Sexual health. BMJ (2003) 1.96
Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl (2006) 1.57
Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol (2010) 1.57
Aminopyrine breath test compared to the MELD and Child-Pugh scores for predicting mortality among cirrhotic patients awaiting liver transplantation. Transpl Int (2003) 1.44
Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification. Trends Biotechnol (2005) 1.40
Genetic variation in morphine analgesic tolerance: a survey of 11 inbred mouse strains. Pharmacol Biochem Behav (2002) 1.34
Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proc Natl Acad Sci U S A (2006) 1.26
The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol (2005) 1.19
Detecting antigens by quantitative immuno-PCR. Nat Protoc (2007) 1.11
The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology (2008) 1.04
Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters. Anal Biochem (2011) 0.96
Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS One (2013) 0.96
Cannabinoid hyperemesis syndrome: case report of a paradoxical reaction with heavy marijuana use. Case Rep Med (2012) 0.95
Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol (2009) 0.94
Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. FEBS Lett (2002) 0.93
Primary cell culture for evaluation of botulinum neurotoxin antagonists. Toxicon (2004) 0.92
Pharmacokinetics of natural mistletoe lectins after subcutaneous injection. Eur J Clin Pharmacol (2010) 0.90
An efficient drug delivery vehicle for botulism countermeasure. BMC Pharmacol (2009) 0.89
Combination of DNA-directed immobilization and immuno-PCR: very sensitive antigen detection by means of self-assembled DNA-protein conjugates. Nucleic Acids Res (2003) 0.88
Nanomechanical devices based on DNA. Angew Chem Int Ed Engl (2002) 0.87
Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg (2011) 0.87
Analysis of the effects of androgens and training on myostatin propeptide and follistatin concentrations in blood and skeletal muscle using highly sensitive immuno PCR. Mol Cell Endocrinol (2010) 0.84
The zinc-dependent protease activity of the botulinum neurotoxins. Toxins (Basel) (2010) 0.84
User configurable microfluidic device for multiplexed immunoassays based on DNA-directed assembly. Anal Chem (2009) 0.83
Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease. Eur J Gastroenterol Hepatol (2015) 0.82
New considerations for an overall approach to treat hepatocellular carcinoma in cirrhotic patients. J Surg Oncol (2003) 0.82
The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology (2010) 0.82
Analytical protein a chromatography as a quantitative tool for the screening of methionine oxidation in monoclonal antibodies. J Pharm Sci (2012) 0.82
Hepatitis B virus and hepatitis C virus infections in Belgium: similarities and differences in epidemics and initial management. Eur J Gastroenterol Hepatol (2013) 0.81
Predictive models of short- and long-term survival in patients with nonbiliary cirrhosis. Liver Transpl (2003) 0.80
Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]. BMC Gastroenterol (2003) 0.80
Growth factor dependent cholinergic function and survival in primary mouse spinal cord cultures. Life Sci (2006) 0.80
Immuno-PCR assays for immunogenicity testing. Biochem Biophys Res Commun (2009) 0.80
An alternative in vivo method to refine the mouse bioassay for botulinum toxin detection. Comp Med (2011) 0.79
Tunable stringency aptamer selection and gold nanoparticle assay for detection of cortisol. Anal Bioanal Chem (2014) 0.79
An acute exposure to a sub-lethal dose of soman triggers anxiety-related behavior in guinea pigs: interactions with acute restraint. Neurotoxicology (2009) 0.79
Acute toxicity of organophosphorus compounds in guinea pigs is sex- and age-dependent and cannot be solely accounted for by acetylcholinesterase inhibition. J Pharmacol Exp Ther (2008) 0.79
Inhibition of neurotransmitter release by peptides that mimic the N-terminal domain of SNAP-25. J Protein Chem (2003) 0.79
Scorpion toxins for the reversal of BoNT-induced paralysis. Bioorg Med Chem Lett (2013) 0.79
Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine. J Pharmacol Exp Ther (2009) 0.79
Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective clinical trials. J Med Virol (2011) 0.78
Kinetic and reaction pathway analysis in the application of botulinum toxin a for wound healing. J Toxicol (2011) 0.77
Monte Carlo simulation of the assembly of bis-biotinylated DNA and streptavidin. Chemphyschem (2003) 0.77
Stochastic simulation and analysis of biomolecular reaction networks. BMC Syst Biol (2009) 0.77
Cytotoxic actions of palytoxin on aortic smooth muscle cells in culture. J Appl Toxicol (2005) 0.76
Serial intrauterine transfusions for a hydropic fetus with severe anemia and thrombocytopenia caused by parvovirus: lessons learned. AJP Rep (2013) 0.76
Detection of orexin A neuropeptide in biological fluids using a zinc oxide field effect transistor. ACS Chem Neurosci (2013) 0.75
Protection by pyridostigmine bromide of marmoset hemi-diaphragm acetylcholinesterase activity after soman exposure. Chem Biol Interact (2010) 0.75
The diagnostic and pharmacological variances of bipolar disorder versus attention-deficit/hyperactivity disorder. Am J Psychiatry (2006) 0.75
Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques. Analyst (2015) 0.75
HBV infection in Belgium: results of the BASL observatory of 1,456 HBsAg carriers. Acta Gastroenterol Belg (2012) 0.75
Measuring Subvisible Particles in Protein Formulations Using a Modified Light Obscuration Sensor with Improved Detection Capabilities. Anal Chem (2015) 0.75
Sexually transmitted infections in practice. Practitioner (2005) 0.75
IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use? Acta Gastroenterol Belg (2011) 0.75
Correction to "Detection of Orexin A Neuropeptide in Biological Fluids Using a Zinc Oxide Field Effect Transistor". ACS Chem Neurosci (2017) 0.75
Inhibition of guinea pig hemi-diaphragm acetylcholinesterase activity by pyridostigmine bromide and protection against soman toxicity. Chem Biol Interact (2005) 0.75
Formation of insoluble particulates in a spray-dried F(ab')(2) fragment. J Pharm Sci (2014) 0.75
Supramolecular DNA-streptavidin nanocircles with a covalently attached oligonucleotide moiety. J Biomol Struct Dyn (2002) 0.75